Dimitri de Vreeze, CEO of dsm-firmenich. Photograph: dsm-firmenic.
The company will retain a 20% equity stake in ANH Companies, in partnership with CVC.
This transaction follows the sale of the Feed Enzymes activities to Novonesis for €1.5 billion in 2025, and marks the final strategic step for dsm-firmenich to become a fully-focused consumer company active in nutrition, health, and beauty. The total enterprise value of ANH, including the prior sale of the Feed Enzymes activities, represents €3.7 billion.
The company intends to launch a new share repurchase programme this quarter to buy back ordinary shares with an aggregate market value of €0.5 billion and reduce its issued capital.
In addition, dsm-firmenich aims to deliver consistent and sustainable dividends to its shareholders. To achieve this, the company has adopted a ‘stable to preferably rising’ dividend policy, reflecting the company’s commitment to long-term value creation. Under this policy, dsm-firmenich aims to maintain a stable dividend of €2.50 per ordinary share and progressively increase dividends over time.
ANH is a global provider of science-based animal nutrition and health solutions. The business offers products ranging from vitamins over premixes, to feed additives that improve animal health, performance, feed efficiency, and sustainability across livestock production. Its solutions help producers deliver high-quality animal protein while reducing environmental impact.
ANH will be split into two new standalone companies, both based in Kaiseraugst, Switzerland: the “Solutions Company”, including performance solutions, premix, and precision services, and the “Essential Products Company”, including vitamins,carotenoids and aroma Ingredients (jointly referred to as the “ANH Companies”). These companies will continue to work closely together, especially with regards to the vitamin supply in the animal nutrition and health value chain.
